Format

Send to

Choose Destination
Biomedicines. 2016 Jul 11;4(3). pii: E14. doi: 10.3390/biomedicines4030014.

Antibody-Drug Conjugates for Cancer Therapy.

Parslow AC1,2, Parakh S3,4,5, Lee FT6, Gan HK7,8,9,10, Scott AM11,12,13,14.

Author information

1
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. adam.parslow@onjcri.org.au.
2
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia. adam.parslow@onjcri.org.au.
3
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. sagun.parakh@onjcri.org.au.
4
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia. sagun.parakh@onjcri.org.au.
5
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria 3084, Australia. sagun.parakh@onjcri.org.au.
6
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. ft.lee@onjcri.org.au.
7
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. hui.gan@onjcri.org.au.
8
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia. hui.gan@onjcri.org.au.
9
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria 3084, Australia. hui.gan@onjcri.org.au.
10
Department of Medicine, University of Melbourne, Melbourne 3010, Australia. hui.gan@onjcri.org.au.
11
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia. andrew.scott@onjcri.org.au.
12
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria 3084, Australia. andrew.scott@onjcri.org.au.
13
Department of Medicine, University of Melbourne, Melbourne 3010, Australia. andrew.scott@onjcri.org.au.
14
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria 3084, Australia. andrew.scott@onjcri.org.au.

Abstract

Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.

KEYWORDS:

ADC; antibody–drug conjugate; cancer; immunotherapy; monoclonal antibodies; resistance

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center